コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 rapy protocol consisting of rituximab and/or intravenous immune globulin.
2 omyelitis can develop despite treatment with intravenous immune globulin.
3 equate responses to conventional therapy and intravenous immune globulin.
4 rticosteroids, immunosuppressive agents, and intravenous immune globulin.
5 mmune-mediated, we evaluated the efficacy of intravenous immune globulin.
6 robably safer, and easier to administer than intravenous immune globulin.
7 Forty-five of the 72 children were receiving intravenous immune globulin.
8 ENOMS) study who had not previously received intravenous immune globulin.
9 received plasmapheresis every other day with intravenous immune globulin 100 mg/kg starting 1 week be
10 dy-surface area) once weekly for 3 weeks and intravenous immune globulin (2 g per kilogram of body we
11 with peripartum cardiomyopathy treated with intravenous immune globulin (2 g/kg) with those of 11 re
12 ents then received conventional therapy with intravenous immune globulin, 2 g per kilogram, as well a
13 baclofen, 3 of 3 treated) and immunotherapy (intravenous immune globulin, 3 of 4 treated and plasmaph
14 Treatment of acute Kawasaki disease with intravenous immune globulin and aspirin reduces the risk
15 d at 2000/mm3 despite empiric treatment with intravenous immune globulin and methylprednisolone, sple
16 Patients in the U.S. study also received intravenous immune globulin and rituximab after transpla
17 ese findings suggest that the combination of intravenous immune globulin and rituximab may prove effe
19 of days of fever, rates of retreatment with intravenous immune globulin, and numbers of adverse even
20 to 20% of patients do not respond to initial intravenous immune globulin, and recommendations for add
21 tion of a nonheparin anticoagulant agent and intravenous immune globulin be considered for the first
22 cyclophosphamide pulse therapy together with intravenous immune globulin before transplant and as par
23 lowed by a monthly infusion of rituximab and intravenous immune globulin for 4 consecutive months.
26 re treated 1 h later with anti-HCV--negative intravenous immune globulin (IGIV) or hepatitis C immune
32 herapy given to patients with MIS-C included intravenous immune globulin (IVIG) (71%), corticosteroid
34 ng and generalized linear models to evaluate intravenous immune globulin (IVIG) as a reference, as co
39 The immunosuppressive mechanism of action of intravenous immune globulin (IVIG) has remained enigmati
40 lled trial was designed to determine whether intravenous immune globulin (IVIG) improves left ventric
41 pregnancy, followed by immunomodulation with intravenous immune globulin (IVIG) in select cases; the
42 tic leukemia (CLL) or multiple myeloma (MM), intravenous immune globulin (IVIg) may be administered t
44 y any such therapy for MIS-C was given) with intravenous immune globulin (IVIG) plus glucocorticoids,
48 BACKGROUND.: We have shown that high-dose intravenous immune globulin (IVIG; 2 g/kg x2 doses)+ritu
49 on assay using human immunoglobulin G (IgG) (intravenous immune globulin [IVIG]), AAV-Go.1 had higher
50 ought to evaluate the effect of therapy with intravenous immune globulin on recovery of left ventricu
51 AD65 antibodies, in random order, to receive intravenous immune globulin or placebo for three months,
52 el was 44+/-30% after the second infusion of intravenous immune globulin (P<0.001 for the comparison
53 se 1-2, single-center study examined whether intravenous immune globulin plus rituximab could reduce
54 eatment with corticosteroids, cidofovir, and intravenous immune globulin, PML progressed rapidly, ren
55 s who failed standard of care treatment with intravenous immune globulin + rituximab with or without
56 variable immunodeficiency who was receiving intravenous immune globulin suddenly had paralysis of al
57 the eight infants, of whom four discontinued intravenous immune globulin supplementation; three of th
59 travenous methylprednisolone to conventional intravenous immune globulin therapy for the routine prim
60 aki disease remains unknown, but fortunately intravenous immune globulin therapy has proved to be eff
62 Therapy for Kawasaki disease resistant to intravenous immune globulin therapy is an area of resear
63 ities and systemic inflammation, but despite intravenous immune globulin therapy, coronary-artery abn
64 apheresis and the administration of low-dose intravenous immune globulin to desensitize 211 HLA-sensi
67 se of immunomodulating therapies was common: intravenous immune globulin was used in 144 (77%), gluco
68 f microvascular damage in dermatomyositis by intravenous immune globulin which appears to intercept t
69 nical trials comparing conventional doses of intravenous immune globulin with the most promising dose